Tag Archives: NIH

IPWatchdog Blog: “In Search of Technology Transfer Best Practices”

The BIO-AUTM Technology Transfer Symposium panel on The Role of Universities, Biotechnology Companies and Technology Transfer in the Innovation Economy included an active debate on issues ranging from increasing the odds for a successful partnership and the pros and cons of the Bayh-Dole Act.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

From Lab to Commercialization: NIH Licenses Offer Another Path

If a biomedical breakthrough occurs within a federal lab, chances are your company can license use of the technology from the National Institutes of Health’s Office of Technology Transfer (OTT).

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

WARF: A Model of Technology Transfer Partnership

The Wisconsin Alumni Research Foundation (WARF) is the oldest technology transfer office in the United States, founded to manage a University of Wisconsin-Madison discovery that eventually eliminated the childhood disease rickets. WARF works with business and industry to transform university research into real products benefiting society at large—the Wisconsin Idea in action (see “Wisconsin Thrives“). Over the years, the foundation has developed a model of technology transfer based on partnership with the UW-Madison and industry, an approach that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Survey on Technology Transfer Shows Complexity of University-Industry Relationships

I sat down with Cartier Esham, Director, Emerging Company Health and Regulatory Affairs at BIO, to discuss BIO’s new survey on licensing trends between universities and companies, part of a larger process of technology transfer. BIO will release the survey at this year’s BIO Investor Forum Technology Transfer Symposium, October 28, 2009. You can learn more about by visiting www.bio.org/ip/techtransfer.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Race to Develop H1N1 Vaccine

Execs from Inovio Biomedical Corporation and Novavax will be speaking at BIF about their experience in the race to develop a vaccine for H1N1. Below are a couple recent developments from these companies: Novavax Inc (NVAX.O) recently reported that its seasonal flu vaccine candidate, which uses virus-like particles, induced an immune response against H3N2, H1N1 and B and was well-tolerated in a mid-stage trial. Read the release. Inovio Biomedical Corp. (INO) said it will team up Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,